SCHEMBL309114

SCHEMBL309114

Cc1cccc(-c2ncc[nH]2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.54
CCR8 P51685 1/20 0.54
NISCH Q9Y2I1 2/20 0.47
MTOR P42345 1/20 0.46
ADK P55263 1/20 0.46
CYP2A6 P11509 1/20 0.43
METAP2 P50579 1/20 0.43
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADRA2A P08913 2/20 0.39
TGFBR1 P36897 6/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
MAPK14 Q16539 2/20 0.37
NOS3 P29474 1/20 0.36
NOS2 P35228 1/20 0.36
ADRA2B P18089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197279 0.86 NISCH (0.54) CCR1CCR8NISCHMTORADK
SCHEMBL13830975 0.86 NISCH (0.39) CCR1CCR8NISCHMTORADK
SCHEMBL29079328 0.79 NISCH (0.47) CCR1CCR8NISCHMTORADK
SCHEMBL14304159 0.78 NISCH (0.46) NISCHMTORADKALDH1A1MEN1
SCHEMBL3050014 0.78 NISCH (0.46) NISCHMTORADKMETAP2ALDH1A1
SCHEMBL4766313 0.78 NISCH (0.46) NISCHMTORADKALDH1A1MEN1
SCHEMBL31374443 0.78 NISCH (0.46) NISCHMTORADKMETAP2ALDH1A1
SCHEMBL24575910 0.76 KDM4E (0.64) CCR1CCR8NISCHMTORADK
SCHEMBL20987228 0.76 NISCH (0.63) CCR1CCR8NISCHMTORADK
SCHEMBL12075550 0.76 KDM4E (0.40) NISCHMTORADKALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137203-A1 GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY ABBOTT DIABETES CARE, INC. (US) 2025-06-26 WO disclosed
US-20250194964-A1 GLUCOSE OXIDASE SENSORS WITH IMPROVED STABILITY ABBOTT DIABETES CARE, INC. 2025-06-19 US disclosed
CN-117881669-A Condensed ring heteroaryl compounds and uses thereof 比西切姆有限公司 2024-04-12 CN disclosed
US-10219730-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2019-03-05 US disclosed
US-10219730-B2 Redox polymers ABBOTT DIABETES CARE INC. (US) 2019-03-05 US disclosed
US-20170227690-A1 NEAR INFRARED RAY ABSORBENT COMPOSITION, NEAR INFRARED RAY CUT FILTER, SOLID IMAGE PICKUP ELEMENT, AND CAMERA MODULE FUJIFILM CORPORATION (JP) 2017-08-10 US disclosed
US-20170227690-A1 NEAR INFRARED RAY ABSORBENT COMPOSITION, NEAR INFRARED RAY CUT FILTER, SOLID IMAGE PICKUP ELEMENT, AND CAMERA MODULE FUJIFILM CORPORATION (JP) 2017-08-10 US disclosed
US-20160296147-A1 Redox Polymers THERASENSE, INC. 2016-10-13 US disclosed
US-20160296147-A1 Redox Polymers THERASENSE, INC. 2016-10-13 US disclosed
US-20160296147-A1 Redox Polymers THERASENSE, INC. 2016-10-13 US disclosed
US-20090145757-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2009-06-11 US disclosed
US-20090145757-A1 Redox Polymers ABBOTT DIABETES CARE INC. 2009-06-11 US disclosed
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR ABBOTT DIABETES CARE INC. 2009-04-16 US disclosed
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR ABBOTT DIABETES CARE INC. 2009-04-16 US disclosed
EP-1230248-B1 TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN THERASENSE INC (US) 2007-06-06 EP disclosed
US-20070007132-A1 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. 2007-01-11 US disclosed
US-20070007132-A1 Transition metal complexes with bidentate ligand having an imidazole ring ABBOTT DIABETES CARE INC. 2007-01-11 US disclosed
US-6605200-B1 Charge transfer compounds comprising polymers such as polyvinylpyridine and/or copolymers coupled to osmium compounds, used as biosensors in redox systems THERASENSE, INC. 2003-08-12 US disclosed
EP-1230248-A2 TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN Therasense, Inc. (US) 2002-08-14 EP disclosed
WO-2001036660-A2 TRANSITION METAL COMPLEXES ATTACHED TO A POLYMER VIA A FLEXIBLE CHAIN THERASENSE, INC. (US) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099434-A1 OXYGEN-EFFECT FREE ANALYTE SENSOR LPO, TXN2, PRDX5 CCR1 4067/4885CCR8 2735/4885NISCH 771/4885
US-20170227690-A1 NEAR INFRARED RAY ABSORBENT COMPOSITION, NEAR INFRARED RAY CUT FILTER, SOLID IMAGE PICKUP ELEMENT, AND CAMERA MODULE C9, SET, CRY1 CCR1 3230/4885CCR8 4074/4885NISCH 779/4885
US-10219730-B2 Redox polymers PPOX, OTC, ME3 CCR1 4831/4885CCR8 4512/4885NISCH 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.